Logo image of GNLX

GENELUX CORP (GNLX) Stock Fundamental Analysis

NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD

2.96  +0.11 (+3.86%)

After market: 2.82 -0.14 (-4.73%)

Fundamental Rating

3

Overall GNLX gets a fundamental rating of 3 out of 10. We evaluated GNLX against 563 industry peers in the Biotechnology industry. While GNLX seems to be doing ok healthwise, there are quite some concerns on its profitability. GNLX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNLX had negative earnings in the past year.
In the past year GNLX has reported a negative cash flow from operations.
GNLX had negative earnings in each of the past 5 years.
In the past 5 years GNLX always reported negative operating cash flow.
GNLX Yearly Net Income VS EBIT VS OCF VS FCFGNLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

GNLX has a worse Return On Assets (-86.04%) than 71.63% of its industry peers.
With a Return On Equity value of -113.68%, GNLX perfoms like the industry average, outperforming 42.02% of the companies in the same industry.
Industry RankSector Rank
ROA -86.04%
ROE -113.68%
ROIC N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNLX Yearly ROA, ROE, ROICGNLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

GNLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNLX Yearly Profit, Operating, Gross MarginsGNLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

6

2. Health

2.1 Basic Checks

GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GNLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GNLX has more shares outstanding
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GNLX Yearly Shares OutstandingGNLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
GNLX Yearly Total Debt VS Total AssetsGNLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -4.36, we must say that GNLX is in the distress zone and has some risk of bankruptcy.
GNLX has a Altman-Z score (-4.36) which is comparable to the rest of the industry.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.36
ROIC/WACCN/A
WACC10.1%
GNLX Yearly LT Debt VS Equity VS FCFGNLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

GNLX has a Current Ratio of 4.57. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.57, GNLX perfoms like the industry average, outperforming 51.60% of the companies in the same industry.
GNLX has a Quick Ratio of 4.57. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GNLX (4.57) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.57
Quick Ratio 4.57
GNLX Yearly Current Assets VS Current LiabilitesGNLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

GNLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.66%, which is quite impressive.
GNLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.29%.
EPS 1Y (TTM)20.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)-95.29%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.42% on average over the next years. This is a very strong growth
GNLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 758.72% yearly.
EPS Next Y-8.11%
EPS Next 2Y-9.82%
EPS Next 3Y3.79%
EPS Next 5Y22.42%
Revenue Next Year-100%
Revenue Next 2Y2473.91%
Revenue Next 3Y2015.23%
Revenue Next 5Y758.72%

3.3 Evolution

GNLX Yearly Revenue VS EstimatesGNLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GNLX Yearly EPS VS EstimatesGNLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNLX. In the last year negative earnings were reported.
Also next year GNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNLX Price Earnings VS Forward Price EarningsGNLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNLX Per share dataGNLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.82%
EPS Next 3Y3.79%

More info and screens

0

5. Dividend

5.1 Amount

GNLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENELUX CORP

NASDAQ:GNLX (5/9/2025, 8:00:01 PM)

After market: 2.82 -0.14 (-4.73%)

2.96

+0.11 (+3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)N/A N/A
Inst Owners14.1%
Inst Owner Change4.55%
Ins Owners16.37%
Ins Owner Change18.68%
Market Cap111.68M
Analysts83.64
Price Target18.36 (520.27%)
Short Float %6.96%
Short Ratio12.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.73%
Min EPS beat(2)-39.67%
Max EPS beat(2)0.21%
EPS beat(4)1
Avg EPS beat(4)-18.49%
Min EPS beat(4)-39.67%
Max EPS beat(4)0.21%
EPS beat(8)1
Avg EPS beat(8)-48.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.43%
EPS NY rev (1m)12.1%
EPS NY rev (3m)14.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13960.1
P/FCF N/A
P/OCF N/A
P/B 4.25
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.04%
ROE -113.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 162.13%
Cap/Sales 4762.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.57
Quick Ratio 4.57
Altman-Z -4.36
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)125.54%
Cap/Depr(5y)76.05%
Cap/Sales(3y)1788.63%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
EPS Next Y-8.11%
EPS Next 2Y-9.82%
EPS Next 3Y3.79%
EPS Next 5Y22.42%
Revenue 1Y (TTM)-95.29%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y2473.91%
Revenue Next 3Y2015.23%
Revenue Next 5Y758.72%
EBIT growth 1Y-31.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.7%
OCF growth 3YN/A
OCF growth 5YN/A